Patient demographics and baseline characteristics
| Characteristic . | Treatment arm . | All (N = 96) . | |
|---|---|---|---|
| PTCy/Tac/MMF (n = 43) . | Tac/MTX (n = 53) . | ||
| Age, y | |||
| Mean (SD) | 72.7 (2.1) | 73.1 (1.9) | 72.9 (2.0) |
| Median (range) | 72.0 (70.1-78.6) | 73.0 (70.1-77.4) | 72.7 (70.1-78.6) |
| Sex, female, n (%) | 17 (39.5) | 17 (32.1) | 34 (35.4) |
| Ethnicity, n (%) | |||
| Not Hispanic or Latino | 41 (95.3) | 53 (100.0) | 94 (97.9) |
| Not reported | 1 (2.3) | 0 (0.0) | 1 (1.0) |
| Unknown | 1 (2.3) | 0 (0.0) | 1 (1.0) |
| Race, n (%) | |||
| Asian | 1 (2.3) | 2 (3.8) | 3 (3.1) |
| White | 40 (93.0) | 51 (96.2) | 91 (94.8) |
| Unknown | 2 (4.7) | 0 (0.0) | 2 (2.1) |
| Karnofsky performance score, n (%) | |||
| <90 | 24 (55.8) | 32 (60.4) | 56 (58.3) |
| HCT-CI, n (%) | |||
| 0 | 11 (25.6) | 7 (13.2) | 18 (18.8) |
| 1-2 | 17 (39.5) | 15 (28.3) | 32 (33.3) |
| 3+ | 15 (34.9) | 27 (50.9) | 42 (43.8) |
| Missing | 0 (0.0) | 4 (7.6) | 4 (4.2) |
| Primary disease, n (%) | |||
| Acute lymphoblastic leukemia | 0 (0.0) | 2 (3.8) | 2 (2.1) |
| Acute myelogenous leukemia | 26 (60.5) | 29 (54.7) | 55 (57.3) |
| Chronic lymphocytic leukemia | 0 (0.0) | 1 (1.9) | 1 (1.0) |
| Myelodysplastic syndrome | 15 (34.9) | 18 (34.0) | 33 (34.4) |
| T-cell NHL | 0 (0.0) | 2 (3.8) | 2 (2.1) |
| Aggressive NHL | 1 (2.3) | 1 (1.9) | 2 (2.1) |
| Burkitt lymphoma | 1 (2.3) | 0 (0.0) | 1 (1.0) |
| Time from diagnosis to transplant (mo) | |||
| Mean (SD) | 8.0 (9.0) | 11.0 (13.6) | 9.6 (11.7) |
| Median (range) | 5.6 (2.8-59.1) | 6.7 (2.9-81.1) | 6.4 (2.8-81.1) |
| Disease risk index, n (%) | |||
| Low | 0 (0.0) | 5 (9.4) | 5 (5.2) |
| Intermediate | 27 (62.8) | 31 (58.5) | 58 (60.4) |
| High or very high | 16 (37.2) | 17 (32.1) | 33 (34.4) |
| Donor type and HLA matching, n (%) | |||
| Related donor 6/6 | 5 (11.6) | 8 (15.1) | 13 (13.5) |
| Unrelated donor 7/8 | 1 (2.3) | 1 (1.9) | 2 (2.1) |
| Unrelated donor 8/8 | 37 (86.0) | 44 (83.0) | 81 (84.4) |
| Received RIC regimen, n (%) | |||
| Fludarabine/busulfan | 17 (39.5) | 21 (39.6) | 38 (39.6) |
| Fludarabine/melphalan | 20 (46.5) | 21 (39.6) | 41 (42.7) |
| Fludarabine/cyclophosphamide | 1 (2.3) | 0 (0.0) | 1 (1.0) |
| Fludarabine/TBI | 0 (0.0) | 4 (7.5) | 4 (4.2) |
| Fludarabine/cyclophosphamide/TBI | 5 (11.6) | 5 (9.4) | 10 (10.4) |
| Missing/unknown | 0 (0.0) | 2 (3.8) | 2 (2.1) |
| Planned posttransplant maintenance therapy, n (%) | |||
| No | 30 (69.8) | 38 (71.7) | 68 (70.8) |
| Yes | 13 (30.2) | 15 (28.3) | 28 (29.2) |
| Characteristic . | Treatment arm . | All (N = 96) . | |
|---|---|---|---|
| PTCy/Tac/MMF (n = 43) . | Tac/MTX (n = 53) . | ||
| Age, y | |||
| Mean (SD) | 72.7 (2.1) | 73.1 (1.9) | 72.9 (2.0) |
| Median (range) | 72.0 (70.1-78.6) | 73.0 (70.1-77.4) | 72.7 (70.1-78.6) |
| Sex, female, n (%) | 17 (39.5) | 17 (32.1) | 34 (35.4) |
| Ethnicity, n (%) | |||
| Not Hispanic or Latino | 41 (95.3) | 53 (100.0) | 94 (97.9) |
| Not reported | 1 (2.3) | 0 (0.0) | 1 (1.0) |
| Unknown | 1 (2.3) | 0 (0.0) | 1 (1.0) |
| Race, n (%) | |||
| Asian | 1 (2.3) | 2 (3.8) | 3 (3.1) |
| White | 40 (93.0) | 51 (96.2) | 91 (94.8) |
| Unknown | 2 (4.7) | 0 (0.0) | 2 (2.1) |
| Karnofsky performance score, n (%) | |||
| <90 | 24 (55.8) | 32 (60.4) | 56 (58.3) |
| HCT-CI, n (%) | |||
| 0 | 11 (25.6) | 7 (13.2) | 18 (18.8) |
| 1-2 | 17 (39.5) | 15 (28.3) | 32 (33.3) |
| 3+ | 15 (34.9) | 27 (50.9) | 42 (43.8) |
| Missing | 0 (0.0) | 4 (7.6) | 4 (4.2) |
| Primary disease, n (%) | |||
| Acute lymphoblastic leukemia | 0 (0.0) | 2 (3.8) | 2 (2.1) |
| Acute myelogenous leukemia | 26 (60.5) | 29 (54.7) | 55 (57.3) |
| Chronic lymphocytic leukemia | 0 (0.0) | 1 (1.9) | 1 (1.0) |
| Myelodysplastic syndrome | 15 (34.9) | 18 (34.0) | 33 (34.4) |
| T-cell NHL | 0 (0.0) | 2 (3.8) | 2 (2.1) |
| Aggressive NHL | 1 (2.3) | 1 (1.9) | 2 (2.1) |
| Burkitt lymphoma | 1 (2.3) | 0 (0.0) | 1 (1.0) |
| Time from diagnosis to transplant (mo) | |||
| Mean (SD) | 8.0 (9.0) | 11.0 (13.6) | 9.6 (11.7) |
| Median (range) | 5.6 (2.8-59.1) | 6.7 (2.9-81.1) | 6.4 (2.8-81.1) |
| Disease risk index, n (%) | |||
| Low | 0 (0.0) | 5 (9.4) | 5 (5.2) |
| Intermediate | 27 (62.8) | 31 (58.5) | 58 (60.4) |
| High or very high | 16 (37.2) | 17 (32.1) | 33 (34.4) |
| Donor type and HLA matching, n (%) | |||
| Related donor 6/6 | 5 (11.6) | 8 (15.1) | 13 (13.5) |
| Unrelated donor 7/8 | 1 (2.3) | 1 (1.9) | 2 (2.1) |
| Unrelated donor 8/8 | 37 (86.0) | 44 (83.0) | 81 (84.4) |
| Received RIC regimen, n (%) | |||
| Fludarabine/busulfan | 17 (39.5) | 21 (39.6) | 38 (39.6) |
| Fludarabine/melphalan | 20 (46.5) | 21 (39.6) | 41 (42.7) |
| Fludarabine/cyclophosphamide | 1 (2.3) | 0 (0.0) | 1 (1.0) |
| Fludarabine/TBI | 0 (0.0) | 4 (7.5) | 4 (4.2) |
| Fludarabine/cyclophosphamide/TBI | 5 (11.6) | 5 (9.4) | 10 (10.4) |
| Missing/unknown | 0 (0.0) | 2 (3.8) | 2 (2.1) |
| Planned posttransplant maintenance therapy, n (%) | |||
| No | 30 (69.8) | 38 (71.7) | 68 (70.8) |
| Yes | 13 (30.2) | 15 (28.3) | 28 (29.2) |
HCT-CI, HCT-specific comorbidity index; MMF, mycophenolate mofetil; NHL, non-Hodgkin lymphoma; SD, standard deviation; TBI, total body irradiation.